Limited ResearchWeight LossMetabolic

KLOW Protocol

KLOW

Four-Peptide Regenerative Blend

Half-life

Not reported

Chain length

Not applicable (peptide combination)

Reference frequency

Once daily for consistent tissue repair support

Research overview

DoseGear research brief

KLOW builds upon GLOW protocol by adding KPV for enhanced anti-inflammatory action. This combination lacks clinical trials on the specific four-peptide formulation despite individual component research. Standard vial contains 80mg blend (50mg GHK-Cu, 10mg TB-500, 10mg BPC-157, 10mg KPV).

Mechanism of action

Each peptide contributes distinct biological pathways: GHK-Cu modulates gene expression for tissue repair, TB-500 enhances cellular migration and wound healing, BPC-157 upregulates growth factors for tissue regeneration, and KPV inhibits NF-κB inflammatory pathway.

Compound background

Development & research timeline

Study windows describe what researchers measured, not when an individual should expect a result.

Origin & development

Marketed multi-peptide blend; a specific developer is not established.

What it is researched for

Proposed inflammation and tissue-repair applications based on ingredient mechanisms; blend validation is not established.

Research observation window

Not reported for the blend.

Reference data

Lyophilized vial injectable protocols

Not personalized dosing instructions

Only injectable vial references are shown. Nasal, topical, and unsupported non-vial schedules are excluded.

Research context	Amount	Frequency	Route
Conservative approach	200mcg total daily	Once daily evening	Subcutaneous
Standard research protocol	200-500mcg total	Once daily	Subcutaneous
Cycling protocol	Per standard dosing	4-6 weeks on, 2-4 weeks off	Subcutaneous

Reference cycle

4-6 weeks

Reference storage

Lyophilized: Room temperature; Reconstituted: 2-8°C, use within 4-6 weeks

Safety context

Reported side effects

Injection site reactions (common even with KPV)
Individual responses vary widely

Contraindications & cautions

No safety studies on four-peptide combination
Long-term effects completely unknown
FDA has not approved any component for therapeutic use

Scientific references

01
Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data
Scientific citationRegenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. International Journal of Molecular Sciences (2018).
02
Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth
Scientific citationGastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth. Journal of Orthopaedic Research (2003).
03
A first-in-human, randomized, double-blind, single- and multiple-dose, phase I study of recombinant human thymosin β4 in healthy Chinese volunteers
Scientific citationA first-in-human, randomized, double-blind, single- and multiple-dose, phase I study of recombinant human thymosin β4 in healthy Chinese volunteers. Journal of Cellular and Molecular Medicine (2021).
04
PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation
Scientific citationPepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology (2008).

This DoseGear profile combines published scientific literature with lyophilized-vial protocol references. Citations are provided for independent review.

Related research profiles

Longevity